Skip to Main Content

Should there be a doorstop in the revolving door between drug makers and regulatory agencies?

Several U.S. senators believe so, and on Thursday they introduced legislation  that would take two steps to slow the pace at which individuals move between the pharmaceutical industry and both the Food and Drug Administration and the Drug Enforcement Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!